Hepatitis B treatment in pregnancy to prevent baby infection
Part of Digestive system, Infections clinical trials.
This study compares two ways of treating hepatitis B in pregnant women to prevent passing the virus to their babies. It tests whether a standard universal treatment approach works better than a quick, point-of-care test-based strategy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older (or the legal adult age in your country).
- You are currently pregnant.
- You plan to attend check-ups at a local health center or rural hospital.
- You live in the area covered by that health center or hospital.
- You have tested positive for hepatitis B surface antigen (HBsAg) during the study screening.
- You are not infected with HIV, are not currently taking hepatitis B medication, and are less than 28 weeks pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.
This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
Hear when a new HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.